Decrease in Reduced-Form Albumin Among Chronic Kidney Disease Patients: New Insights in Cardiovascular Complications

Hiroyuki Terawaki, Seiichi Era, Masaaki Nakayama, Tatsuo Hosoya

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

From the perspective of free cysteine residue (Cys-34), human serum albumin (HSA) comprises a mixture of human mercaptoalbumin (HMA), in which the Cys-34 is not oxidized, human non-mercaptoalbumin (HNA)-1, which has a disulfide bond that can be reversibly oxidized, mainly by cysteine, and HNA-2, which is strongly oxidized to form sulfinic (-SO2H) or sulfonic (-SO3H) species. We have developed a convenient high-performance liquid chromatographic (HPLC) system for the clear separation of HSA into HMA, HNA-1 and HNA-2, and we have studied the dynamic changes of HSA-redox under various states of chronic kidney disease, in both a clinical and an experimental setting. In this article, we discuss the relationship between HSA-redox (especially the decrease of the reduced form), dialyzable uremic toxins and incident cardiovascular disease based on our recent investigations.

Original languageEnglish
Pages (from-to)156-160
Number of pages5
JournalTherapeutic Apheresis and Dialysis
Volume15
Issue number2
DOIs
Publication statusPublished - 2011 Apr

Keywords

  • Cardiovascular disease
  • Chronic kidney disease
  • Oxidative stress
  • Redox state of albumin

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Fingerprint Dive into the research topics of 'Decrease in Reduced-Form Albumin Among Chronic Kidney Disease Patients: New Insights in Cardiovascular Complications'. Together they form a unique fingerprint.

  • Cite this